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Introduction
A novel type of metallo-β-lactamase (MBL), New Delhi
metallo-β-lactamase 1 (NDM-1), was first identified
in a Klebsiella pneumoniae isolated from a Swedish
patient who had been admitted to an Indian hospital
in 2009.1 Since then, Enterobacteriaceae carrying this
novel MBL have been identified worldwide,2,3 espe-
cially in patients with a traveling history to or a hospi-
talization history in India or Pakistan.2
Enterobacteriaceae carrying the gene encoding
NDM-1, blaNDM-1, are not only resistant to carba-
penem, but also highly resistant to many classes of
antibiotics due to the coexistence of multiple resistant
mechanisms.2 The blaNDM-1 is located on large plasmids
with various sizes.1 Most of the plasmids carrying
blaNDM-1 could readily be transferred to Escherichia
coli,2 and may also be transferred to other Enterobac-
teriaceae. To date, Enterobacteriaceae that have been
found to carry blaNDM-1 include K. pneumoniae, 
K. oxytoca, E. coli, Enterobacter cloacae, Proteus spp.,
Citrobacter freundii, Morganella morganii and
Providencia spp.3 In addition to the dissemination of
blaNDM-1 via plasmid spreading, some K. pneumoniae
isolates carrying blaNDM-1 were clonal, indicating that
these strains have the potential to cause epidemics.2
A worrisome condition is that blaNDM-1 has also been
found in Acinetobacter baumannii, which is notorious
for its intrinsic multidrug resistance.4 These conditions
indicate the importance of prompt identification of bac-
teria carrying blaNDM-1 and implementation of strict
infection control measures, especially for patients re-
turning from endemic areas,3 to prevent its transmis-
sion in the hospital setting. Here, we report the first
identification and management of a patient colonized
with K. pneumoniae carrying blaNDM-1 in Taiwan.
Case Report
A 38-year-old Taiwanese man, with irrelevant past
history, suffered from gun-shot injury to his right 
lateral abdominal wall on the 2nd day after arriving 
in New Delhi. He received hepatorrhaphy, right
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hemicolectomy with primary anastomosis and tran-
siently stayed in the intensive care unit at a medical
center in Delhi for 8 days. He was then repatriated to
Taiwan and was admitted to Taipei Veterans General
Hospital. At presentation, he was well in appearance,
afebrile, and with stable hemodynamic status. On exam-
ination, there were 2 insertion sites for prior drainage
tubes with some discharge over the right and left lower
quadrants of the abdomen, and a well-healed surgical
wound over the central abdomen; otherwise, there
were no remarkable abnormalities.
Laboratory investigations showed a white blood
cell count of 13,800/mm3 (with 68.2% neutrophils),
hemoglobin of 13.8 mg/dL, platelet count of
468,000/mm3, blood urea nitrogen of 12 mg/dL,
creatinine of 0.98 mg/dL, and glucose of 95 mg/dL.
Due to his traveling and hospitalization history, he was
admitted to a single isolated room for close monitor-
ing. The health care providers followed strict contact
precaution measures while caring for this patient.
Urine, stool and pus cultures were sent to the Centers
for Disease Control (CDC) of Taiwan for surveillance
of blaNDM-1-harboring bacteria. K. pneumoniae isolates
carrying blaNDM-1 were isolated from 2 consecutive
fecal samples from anal swabs. The blaNDM-1 was
detected by PCR with the use of previously described
primers1 and verified by gene sequencing and analysis.
After hospitalization for 5 days, the patient’s
wounds were completely healed. He was discharged
in a stable condition and in accordance with the sug-
gestion from the Taiwan CDC. His fecal samples will
be screened weekly by the Taiwan CDC for blaNDM-1-
carrying bacteria until the results come back negative.
Discussion
It is currently unknown where and how the patient
acquired K. pneumoniae with blaNDM-1. A molecular
epidemiological study comparing the strain from this
patient with reported strains from India might provide
a clue as to its origin. Nevertheless, the results from
our case imply that implementation of systematic sur-
veillance and control measures for patients (even asymp-
tomatic ones) from endemic areas may be beneficial in
preventing the spread of carbapenem-resistant bacte-
ria. However, this approach may become problematic
when the number of endemic areas grows rapidly.3
Most blaNDM-1-carrying Enterobacteriaceae are
isolated from patients with urinary tract infection, pneu-
monia or bloodstream infections.2 Although detailed
information regarding the therapy of such patients has
not been reported, to date, only 1 patient was reported
to have succumbed to the infection,3 indicating that
blaNDM-1-carrying Enterobacteriaceae might not be as
virulent as their counterparts. In addition, these bac-
teria can be isolated from asymptomatic patients.1 Our
patient did not have symptoms and signs of infection
during his hospitalization, suggesting that the bac-
terium is most likely a colonizer.
To date, it remains unresolved as to how long a
patient colonized with carbapenem-resistant Entero-
bacteriaceae (CRE) should be managed under contact
precautions.5,6 There is no recommendation to quar-
antine the asymptomatic patient harboring CRE, either
in hospital or in the community setting. Neither is
there any suggestion with regard to decolonization of
these carbapenem-resistant bacteria due to limited
treatment options (polymyxins, tigecycline) and insuf-
ficient data to warrant their routine use.6 However,
infection control and prevention measures, such as
education of staff and patients, environmental sterili-
zation, surveillance, and contact precautions, should be
vigorously reinforced when caring for these patients.6
Since K. pneumoniae is a commensal bacterium, it is
currently unknown how long this bacterium carrying
blaNDM-1 will colonize the human gut. A periodic cul-
ture of fecal samples may be helpful in answering this
question.
The importation and spread of bacteria carrying
blaNDM-1 to Taiwan is foreseeable due to globaliza-
tion3 with heavy international travel and the charac-
teristics of the bacteria, which are commensal flora in
asymptomatic patients. However, systematic surveil-
lance and infection control measures in patients with
high risk of acquisition might thwart their transmis-
sion. As the first case colonized with bacteria carrying
blaNDM-1 appeared in Taiwan, the public health depart-
ment, administrative department, and clinicians should
be reminded and be organized to implement a disci-
plinary protocol to monitor the possibility of an epi-
demic, and to limit the impact of the emergent medical
challenge.
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